We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

16 hedge funds and large institutions have $2.43M invested in Hepion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 → 16 (+1)

39% less capital invested

Capital invested by funds: $4M → $2.43M (-$1.58M)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$77.2K
2
VF
Virtu Financial
New York
+$47.3K
3
JP Morgan Chase
JP Morgan Chase
New York
+$4.16K
4
Bank of America
Bank of America
North Carolina
+$378

Top Sellers

Rank Fund Capital Flow
1
OCA
Octagon Capital Advisors
New York
-$337K
2
Morgan Stanley
Morgan Stanley
New York
-$38.6K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$19.5K
4
Osaic Holdings
Osaic Holdings
Arizona
-$16.7K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.35M +$77.2K +408 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$520K -$19.5K -103 -3%
BlackRock
3
BlackRock
New York
$269K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$114K – – –
State Street
5
State Street
Massachusetts
$51.3K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$47.9K – – –
VF
7
Virtu Financial
New York
$41K +$47.3K +250 New
Morgan Stanley
8
Morgan Stanley
New York
$9.36K -$38.6K -204 -78%
PNC Financial Services Group
9
PNC Financial Services Group
Pennsylvania
$9.33K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$5.24K -$2.27K -12 -27%
JP Morgan Chase
11
JP Morgan Chase
New York
$3.61K +$4.16K +22 New
Group One Trading
12
Group One Trading
Illinois
$1.11K – – –
FDCDDQ
13
Federation des caisses Desjardins du Quebec
Quebec, Canada
$567 – – –
Osaic Holdings
14
Osaic Holdings
Arizona
$369 -$16.7K -88 -98%
Bank of America
15
Bank of America
North Carolina
$369 +$378 +2 New
Wells Fargo
16
Wells Fargo
California
$107 – – –
Barclays
17
Barclays
United Kingdom
$52 – – –
UBS Group
18
UBS Group
Switzerland
$6 – – –
AF
19
Allworth Financial
California
$4 – – –
GRP
20
Global Retirement Partners
California
$3 – – –
HIA
21
Harbor Investment Advisory
Maryland
$3 – – –
S
22
SignatureFD
Georgia
$3 – – –
OCA
23
Octagon Capital Advisors
New York
– -$337K -1,350 Closed
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
– -$378 -2 Closed

HEPA Hedge Fund Activity: Q4 2023 in Review

16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2023, worth a combined $2.43M — down 39% from $4M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new HEPA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, adding an estimated $77.2K. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $337K sold.

  • 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2023, up from 15 in Q3 2023.
  • Funds reported $2.43M of Hepion Pharmaceuticals stock for Q4 2023, down 39% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +1 holder.
  • The largest Hepion Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $77.2K added.
  • The largest Hepion Pharmaceuticals seller in Q4 2023 was Octagon Capital Advisors, an estimated $337K sold.

Based on aggregated 13F filings for Q4 2023.